Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.13 USD | +1.43% | -2.74% | -69.22% |
04-18 | Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year | MT |
04-18 | Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States | CI |
Business Summary
Number of employees: 16
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ilya Rachman
CEO | Chief Executive Officer | 52 | 31/12/11 |
Gabriel Morris
DFI | Director of Finance/CFO | 38 | 28/02/21 |
Graham Ross
CTO | Chief Tech/Sci/R&D Officer | 64 | 31/05/21 |
Nandan Oza
PRN | Corporate Officer/Principal | 61 | 30/04/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jane Buchan
BRD | Director/Board Member | 60 | 30/06/21 |
Jason Hsu
BRD | Director/Board Member | 50 | 31/12/12 |
Magda Marquet
BRD | Director/Board Member | 65 | 31/05/21 |
Carey Ng
BRD | Director/Board Member | 45 | 31/10/19 |
Helen Adams
BRD | Director/Board Member | 65 | 31/05/21 |
Ilya Rachman
CEO | Chief Executive Officer | 52 | 31/12/11 |
Gabriel Morris
DFI | Director of Finance/CFO | 38 | 28/02/21 |
Director/Board Member | 39 | 21/08/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,468,783 | 14,277,691 ( 53.94 %) | 72,363 ( 0.2734 %) | 53.94 % |
Company contact information
Immix Biopharma, Inc.
11400 West Olympic Boulevard Suite 200
90064, Los Angeles
+
http://www.immixbio.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.22% | 56.22M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- IMMX Stock
- Company Immix Biopharma, Inc.